Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan 24;6(2):371-90.
doi: 10.3390/v6020371.

HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine

Affiliations
Review

HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine

Xiao-Peng Zhu et al. Viruses. .

Abstract

Herpes simplex virus type 2 (HSV-2), a globally sexually transmitted virus, and also one of the main causes of genital ulcer diseases, increases susceptibility to HIV-1. Effective vaccines to prevent HSV-2 infection are not yet available, but are currently being developed. To facilitate this process, the latest progress in development of these vaccines is reviewed in this paper. A summary of the most promising HSV-2 vaccines tested in animals in the last five years is presented, including the main factors, and new ideas for developing an effective vaccine from animal experiments and human clinical trials. Experimental results indicate that future HSV-2 vaccines may depend on a strategy that targets mucosal immunity. Furthermore, estradiol, which increases the effectiveness of vaccines, may be considered as an adjuvant. Therefore, this review is expected to provide possible strategies for development of future HSV-2 vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of pathogenesis and immune responses of HSV-2 in vaccine development. (A) HSV-2 glycoproteins, especially gB and gD, are widely used to develop subunit vaccine and peptide vaccine. DNA has also been frequently used for vaccine development; (B) The transcription and translation of the genes lead to HSV-2 shedding and recurrent episodes; (C) The ability of gD to induce specific antibody is the strongest. The combination of gD with HVEM triggers immediate innate immune response, which leads to subsequent adaptive immune response.
Figure 2
Figure 2
Factors of developing an effective vaccine. (A) The size of the circle represents the importance of the factor; (B) The progress in HSV-2 pathogenesis will promote the development of vaccine formulation; (C) The progress in HSV-2 immune response will promote the development of vaccine formulation; (D) The progress in HSV-2 pathogenesis will promote the development of immunization route; (E) The progress in HSV-2 immune response will promote the development of immunization route.

Similar articles

Cited by

References

    1. Looker K.J., Garnett G.P., Schmid G.P. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. WHO. 2008;86:805–812. - PMC - PubMed
    1. Gupta R., Warren T., Wald A. Genital herpes. Lancet. 2007;370:2127–2137. doi: 10.1016/S0140-6736(07)61908-4. - DOI - PubMed
    1. Mark K.E., Wald A., Magaret A.S., Selke S., Kuntz S., Huang M.L., Corey L. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J. Acquir. Immune Defic. Syndr. 2010;54:482–488. doi: 10.1097/QAI.0b013e3181d91322. - DOI - PMC - PubMed
    1. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. Aids. 2006;20:73–83. doi: 10.1097/01.aids.0000198081.09337.a7. - DOI - PubMed
    1. Horbul J.E., Schmechel S.C., Miller B.R.L., Rice S.A., Southern P.J. Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture. PLoS One. 2011;6:e22638. - PMC - PubMed

Publication types

MeSH terms